意大利索林集團Sorin Group
一家意大利致力于醫療技術領域的跨國公司,它最近宣布將推出一種在其種類中堪稱革命性的人工心臟瓣膜。一種能不打開胸部或停止心臟而被植入患者的產品。所以簡而言之,或許不必實施外科縫合術。這是一種生物學支持結構的瓣膜,由于它利用了其它的醫療技術大約有十年,其基本概念已經得到完善并經過試驗。很長的孵化期使之能科學地展示其可靠性,現在對之已經不再有疑義了。
Sorin Group is a global company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.
The Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.